Investigators at Joslin Diabetes Center first identified genes that were altered in their level of expression in islets isolated from people with type 2 diabetes.
The researchers then went on to show that when they created a defect in one of these genes called ARNT in mice, the mice developed alterations in insulin secretion that were like those in humans with type 2 diabetes.

The ARNT ( aryl hydrocarbon receptor nuclear translocator ) gene is a member of a family of transcription factors essential for normal embryonic development and also is involved in response to conditions of hypoxia and certain environmental toxins, such as dioxin.
Transcription factors like ARNT control the expression and activity of many other genes in the cell and thus serve as master regulators of cell function. As a component of the response to toxins and hypoxic stress, ARNT is also at a potential site to integrate genetic and environmental insults.

" While previous work suggested defects in other pathways in a small percentage of people with type 2 diabetes, what was unexpected was that the islets from all of the people with type 2 diabetes studied demonstrated a marked down-regulation of the nuclear transcription factor ARNT," said C. Ronald Kahn, director of Joslin Diabetes Center and at Harvard Medical School, who led the research team. " These findings provide new insights into the pathogenesis of the most common forms of type 2 diabetes and a possible new target for treatment of this disease," he said.

The investigators then went on to demonstrate that reducing the level of the ARNT gene in beta cells in culture also produced defects in glucose-stimulated insulin release and alterations in islet gene expression that mimic those in humans with type 2 diabetes.

" This study represents the first use of DNA chips to study islets of diabetic patients and the first demonstration of an important role for ARNT and altered gene expression in impaired beta-cell function in the pathogenesis of human type 2 diabetes," Kahn said.

Type 2 diabetes is the most common human metabolic disease, affecting almost 200 million people worldwide, and is increasing at epidemic rates in the U.S. and worldwide.
The pathogenesis of type 2 diabetes involves two defects: insulin resistance and impaired functioning of the insulin-producing beta cells in the pancreas. Both of these have some element of genetic programming. In 2 to 5 percent of patients with a form of type 2 diabetes known as maturity onset diabetes of the young ( MODY ), defects involving genes essential for beta-cell function have been found.
However, in the majority of patients with the common variety of type 2 diabetes, the genetic defects of this beta-cell defect remain unknown.

Source: Joslin Diabetes Center, 2005


XagenaMedicine2005